JANX (STOCKS)
Janux Therapeutics, Inc. Common Stock
$15.287200
+0.357200 (+2.39%)
Prev close: $14.930000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David Campbell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $905.78M
- Employees
- 103
- P/E (TTM)
- -8.13
- P/B (TTM)
- 0.94
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
14
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.51 | $-0.66 | +0.1471 | +22.39% |
|
Sep 2025 (Q3)
|
$-0.39 | $-0.63 | +0.2397 | +38.07% |
|
Jun 2025 (Q2)
|
$-0.55 | $-0.48 | -0.0740 | -15.55% |
|
Mar 2025 (Q1)
|
$-0.38 | $-0.40 | +0.0223 | +5.54% |
Financial Statements
| Revenues | $10.00M |
| Benefits Costs and Expenses | $123.63M |
| Costs And Expenses | $123.63M |
| Nonoperating Income/Loss | $44.04M |
| Operating Expenses | $167.67M |
| Research and Development | $125.90M |
| Other Operating Expenses | $41.77M |
| Operating Income/Loss | -$157.67M |
| Income/Loss From Continuing Operations After Tax | -$113.63M |
| Income/Loss From Continuing Operations Before Tax | -$113.63M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$113.63M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$113.63M |
| Net Income/Loss Available To Common Stockholders, Basic | -$113.63M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.83 |
| Diluted Earnings Per Share | -$1.83 |
| Basic Average Shares | 61,966,999 |
| Diluted Average Shares | 61,966,999 |
| Assets | $1.00B |
| Current Assets | $975.89M |
| Noncurrent Assets | $25.68M |
| Fixed Assets | $3.85M |
| Other Non-current Assets | $21.83M |
| Liabilities | $44.74M |
| Current Liabilities | $25.00M |
| Accounts Payable | $4.97M |
| Wages | $4.59M |
| Other Current Liabilities | $15.44M |
| Noncurrent Liabilities | $19.75M |
| Equity | $956.82M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $956.82M |
| Liabilities And Equity | $1.00B |
| Net Cash Flow From Operating Activities | -$82.24M |
| Net Cash Flow From Operating Activities, Continuing | -$82.24M |
| Net Cash Flow From Investing Activities | -$300.98M |
| Net Cash Flow From Investing Activities, Continuing | -$300.98M |
| Net Cash Flow From Financing Activities | $4.95M |
| Net Cash Flow From Financing Activities, Continuing | $4.95M |
| Net Cash Flow | -$378.27M |
| Net Cash Flow, Continuing | -$378.27M |
| Comprehensive Income/Loss | -$111.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$111.47M |
| Other Comprehensive Income/Loss | $2.15M |